Biodistribution and Pharmacokinectics of Liposomes and Exosomes in a Mouse Model of Sepsis

Exosomes have attracted considerable attention as drug delivery vehicles because their biological properties can be utilized for selective delivery of therapeutic cargoes to disease sites. In this context, analysis of the in vivo behaviors of exosomes in a diseased state is required to maximize their therapeutic potential as drug delivery vehicles. In this study, we investigated biodistribution and pharmacokinetics of HEK293T cell-derived exosomes and PEGylated liposomes, their synthetic counterparts, into healthy and sepsis mice. We found that biodistribution and pharmacokinetics of exosomes were significantly affected by pathophysiological conditions of sepsis compared to those of liposomes. In the sepsis mice, a substantial number of exosomes were found in the lung after intravenous injection, and their prolonged blood residence was observed due to the liver dysfunction. However, liposomes did not show such sepsis-specific effects significantly. These results demonstrate that exosome-based therapeutics can be developed to manage sepsis and septic shock by virtue of their sepsis-specific in vivo behaviors.

Automated summary

Exosomes have potential as drug delivery vehicles due to their ability to selectively deliver therapeutic cargoes to disease sites. The in vivo behaviors of exosomes are affected by pathophysiological conditions, and exosomes exhibit specific behaviors in sepsis mice compared to liposomes. This suggests that exosome-based therapeutics may be effective in managing sepsis and septic shock.